CALMARE THERAPEUTICS INCORPORATED (OTCMKTS:CTTC) Files An 8-K Other Events
ITEM 8.01
As set forth in the Registrant’s Form 10-K for the fiscal year ended December 31, 2016 (the “2016 10-K”), on August 22, 2014, GEOMC filed a complaint against the Registrant in the United States District Court for the District of Connecticut. The allegations included in that complaint, as amended, are described in the 2016 10-K. On September 29, 2017, the District Court entered a final judgment that awarded GEOMC, among other relief, monetary damages of $4,673,406, in addition to pre-judgment interest of $5,678,764, with both amounts totaling $10,352,170. On May 25, 2018, the District Court entered an order awarding GEOMC attorneys’ fees in the amount of $836,442.05 and costs in the amount of $5,231.80.
Calmare appealed both the final judgment and the May 25, 2018 order awarding GEOMC attorneys’ fees and costs to the United States Court of Appeals for the Second Circuit. As set forth in the Registrant’s Forms 8-K dated March 18, 2019 and dated June 10, 2019, the United States Court of Appeals for the Second Circuit on March 12, 2019 vacated the District Court’s judgment and remanded the case to the District Court for further proceedings.
On October 30, 2019, the United States Court of Appeals for the Second Circuit vacated the District Court’s May 25, 2018 order awarding GEOMC attorneys’ fees and costs and remanded the case to the District Court for further proceedings.
The information in this Item 8.01 of this Form 8-K is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section. The information in this Item 8.01 of this Form 8-K also shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except to the extent that the Company specifically incorporates it by reference.
About CALMARE THERAPEUTICS INCORPORATED (OTCMKTS:CTTC)
Calmare Therapeutics Incorporated (CTI) is a medical device company. The Company is engaged in developing and commercializing products and technologies for chronic neuropathic pain and wound care affliction patients. The Company’s medical device, the Calmare Pain Therapy Device (the Calmare Device), is a non-invasive and non-addictive modality that can treat chronic, neuropathic pain. The Company offers a portfolio of technologies in life, electronic, nano and physical sciences. The Company’s technology portfolio includes CALMARE pain therapy treatment, neuroprotection and cognitive enhancement, sexual dysfunction therapeutic, skin pigment enhancer, wound sealant, preparation of ordered multi-layer films, silica thin films, structural steel fissure detection paint, public key encryption, growing single crystals, and video compression and moving picture experts group (MPEG)-4. The Company’s subsidiary is Vector Vision, Inc.